Pacific Biosciences of California, INC 10-Q quarterly reports

Pacific Biosciences of California, Inc. reported a 2% decrease in total revenue for Q2 2026 compared to the prior year, alongside a significant operating loss, while implementing restructuring measures and leadership changes.

Pacific Biosciences reports flat Q1 2026 revenue of $37.2 million and a narrowed net loss of $8.3 million following strategic restructuring.

Pacific Biosciences reports a slight revenue increase to $115.4 million for the nine months ended September 30, 2025, but operating loss significantly widens to $512.7 million due to substantial restructuring charges and asset impairments.

Pacific Biosciences of California, Inc. reported a significant net loss in Q2 2025, driven by substantial non-cash restructuring charges, despite modest revenue growth and strategic progress in its HiFi sequencing platforms.

Pacific Biosciences' Q1 2025 results reveal a revenue decrease and substantial operating losses as the company undergoes a strategic restructuring.

Pacific Biosciences' Q3 2024 results show a decrease in revenue and a significant goodwill impairment charge, alongside ongoing restructuring efforts.

Pacific Biosciences' Q2 2024 results reveal a decrease in revenue and a significant goodwill impairment charge, leading to a substantial net loss, while the company initiates restructuring efforts to reduce operating expenses.

Pacific Biosciences' first quarter 2024 results show a slight decrease in revenue but an improvement in gross margin compared to the same period last year.